Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

Next Previous
Trial Profile

A Phase 1/2a, Open-Label, Dose Escalation Trial of GEN3017 With Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 03 Mar 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GEN3 017 (Primary)
  • Indications Hodgkin's disease; Non-Hodgkin's lymphoma; T-cell lymphoma
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Genmab

Most Recent Events

  • 24 Feb 2025 Status changed from active, no longer recruiting to discontinued as Genmab discontinued GEN3017 program following a strategic re-evaluation of Genmab's portfolio.
  • 18 Nov 2024 Status changed from recruiting to active, no longer recruiting.
  • 01 Dec 2023 Planned End Date changed from 30 Jun 2028 to 31 Dec 2032.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top